Home

Discovering biology’s relationships, curing disease.

We are an end-to-end biotech developing transformational medicines, with technology at our core.

Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell multi-omics directly from patient tissue, functional assays and machine learning to drive at disease understanding — from cause to cure.

Our science

Medicines born from high-resolution biology, machine learning and clinical insights.

Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

Read about our science and disease focus
Image of Relation employee

Our team

Interdisciplinary collaboration.
Immense impact.

Relation is led by experienced drug developers, computational scientists and entrepreneurs with experience across biotech, pharma, venture and academic research. We have a hunger to transform drug development as we know it — because the patient is waiting.

Learn about our team
Image of Relation employees

Timeline

  1. Jan 2020

    Company founded by Charles Roberts, Benjamin Swerner and Jake Taylor-King

  2. Sept 2020

    Relation, Yoshua Bengio, Mila and Scripps Research awarded grant from Bill and Melinda Gates Foundation

  3. Mar 2022

    Relation awarded access to NVIDIA's CAMBRIDGE-1, the UK's most powerful supercomputer, to power digital biology breakthroughs

  4. April 2022

    David Roblin moves from Non-Executive Director to CEO

  5. June 2022

    $25M raised led by DCVC and Magnetic

  6. Feb 2023

    Nobel laureate Sir Paul Nurse opens Relation Labs

  7. March 2023

    Relation announces osteoporosis as its first indication

  8. March 2024

    Relation announces $60M seed financing closure

Join our team.

We are seeking world-class talent across biology, machine learning and drug discovery. Explore our opportunities here.

View open positions

Read our news

Read more

  1. A community effort to track commercial single-cell and spatial ’omic technologies and business trends

    Nature Biotechnology

    Scientific publication 17 Jul 2024

  2. Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

    GlobalNewswire

    Press release 14 Mar 2024

  3. Exclusive: ‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work

    Endpoints News

    In the news 13 Mar 2024

  4. Season combinatorial intervention predictions with Salt & Peper

    OpenReview

    Scientific publication 03 Mar 2024